Renal Cell Carcinoma Antibody (66.4.C2): sc-65231

Renal Cell Carcinoma Antibody (66.4.C2) is a mouse monoclonal IgG2b antibody that detects Renal Cell Carcinoma protein (RCC) of human origin by western blotting (WB), immunofluorescence (IF), and immunohistochemistry. Anti-RCC antibody (66.4.C2) is available as a non-conjugated format. Renal cell carcinoma, the most prevalent form of kidney cancer in adults, arises from the renal tubule and is characterized by atypical, polygonal cells that often form distinct structures such as cords, papillae, and nests. These tumor cells are notable for their accumulation of glycogen and lipids, which results in a clear cytoplasm. Renal cell carcinoma is associated with increased secretion of vasoactive substances, including renin, which can lead to arterial hypertension and stimulate erythropoietin production, potentially resulting in polycythemia. The glycoprotein gp200, expressed in 93% of primary and 84% of metastatic renal cell carcinomas, plays a crucial role in cancer pathology, localizing along the brush border of the proximal tubule and luminal surface of Bowman′s capsule, highlighting significance in renal function and tumor progression. While renal cell carcinoma is often resistant to conventional therapies such as radiation and chemotherapy, some cases may respond to immunotherapy, with agents like α-interferon and interleukin-2 showing promise in inhibiting tumor growth, including in metastatic cases. Additionally, gp200 expression is not limited to renal cell carcinoma; gp200 is also observed in other carcinomas, such as mammary carcinomas, teratocarcinomas, and parathyroid adenomas, making gp200 a valuable target for research and therapeutic strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Renal Cell Carcinoma Antibody (66.4.C2) References:

1. Alpha-interferon 2a and 1 3-cis-retinoic acid for the treatment of metastatic renal cell carcinoma.  |  Wong, M., et al. 2002. Intern Med J. 32: 158-62. PMID: 11951927
2. Chromophobe renal cell carcinoma with extensive calcification and ossification.  |  Wu, SL., et al. 2002. Ann Diagn Pathol. 6: 244-7. PMID: 12170456
3. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.  |  Flanigan, RC., et al. 2004. J Urol. 171: 1071-6. PMID: 14767273
4. How I do it: evaluating renal masses.  |  Israel, GM. and Bosniak, MA. 2005. Radiology. 236: 441-50. PMID: 16040900
5. Multifocal metastases of recurrent renal cell carcinoma successfully treated with a combination of low dose interleukin-2, alpha-interferon and radiotherapy.  |  Sawada, N., et al. 2005. Int J Urol. 12: 994-5. PMID: 16351657
6. Renin-producing renal cell carcinoma.  |  Steffens, J., et al. 1990. Eur Urol. 18: 56-60. PMID: 2205501
7. Changes of vasoactive substances following embolization for renal cell carcinoma.  |  Nakada, T., et al. 1988. Int Urol Nephrol. 20: 569-76. PMID: 3229930
8. Inferior vena cava tumor thrombus in renal cell carcinoma: staging by MR imaging and impact on surgical treatment.  |  Oto, A., et al. 1998. AJR Am J Roentgenol. 171: 1619-24. PMID: 9843299
9. Invasiveness of renal cell carcinoma--an in vitro model.  |  Yang, AH., et al. 1990. Exp Mol Pathol. 53: 191-202. PMID: 2257928